{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:50:46Z","timestamp":1792795846554,"version":"4.5.0"},"reference-count":144,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Medulloblastoma (MB) is the most common pediatric embryonal tumor of the central nervous system. MB grows rapidly in the cerebellum and causes devastating disease in young children. The presence of high-risk molecular or histopathological features is associated with frequent recurrence, resistance to therapy, and poor prognosis, with few experiencing long-term survival. The current standard of care for MB includes surgical resection, radiation, and chemotherapy; however, there remains a need for more specific and effective treatment strategies, especially in recurrent disease. Promising developments in immune checkpoint inhibition have recently entered clinical trials, yet few address MB. Classic immune checkpoints such as Programmed Cell Death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) have recently been identified as potential therapeutic targets for slowing MB progression in the recurrent setting. Preclinical and clinical studies have identified additional targets such as B7-H3, V-domain Ig Suppressor of T-cell Activation (VISTA), lymphocyte-activated gene 3 (LAG-3), P-selectin glycoprotein 1 (PSGL-1), and T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) expression in the MB TME. This review summarizes current preclinical and clinical prospects for immune checkpoint inhibition via direct antibody targeting for the treatment of MB and describes the proposed next generation of immune checkpoint inhibitors.<\/jats:p>","DOI":"10.3389\/fonc.2026.1725230","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T10:27:05Z","timestamp":1778236025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune checkpoint inhibitors in medulloblastoma: current updates in preclinical and clinical developments"],"prefix":"10.3389","volume":"16","author":[{"given":"Rachel L.","family":"Welch","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Albert Einstein College of Medicine","place":["Bronx, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Moziak","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Albert Einstein College of Medicine","place":["Bronx, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Albert Einstein College of Medicine","place":["Bronx, NY, United States"]},{"name":"Marilyn and Stanley M. Katz Institute for Immunotherapy for Cancer and Inflammatory Disorders, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine","place":["Bronx, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Albert Einstein College of Medicine","place":["Bronx, NY, United States"]},{"name":"Marilyn and Stanley M. Katz Institute for Immunotherapy for Cancer and Inflammatory Disorders, Montefiore Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine","place":["Bronx, NY, United States"]},{"name":"Department of Pediatrics, Albert Einstein College of Medicine\/Montefiore Medical Center","place":["Bronx, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.pedca15-ia19","article-title":"Medulloblastoma","volume":"5","author":"Northcott","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/neuonc\/noaf168","article-title":"CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021","volume":"27","author":"Price","year":"2025","journal-title":"Neuro-Oncology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2012.04.009","article-title":"The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children","volume":"19","author":"Smoll","year":"2012","journal-title":"J Clin Neurosci"},{"key":"B4","volume-title":"Medulloblastoma","author":"Mahapatra","year":"2025"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12010061","article-title":"Subgroup-specific diagnostic, prognostic, and predictive markers influencing pediatric medulloblastoma treatment","volume":"12","author":"Ray","year":"2022","journal-title":"Diagnostics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00581-1","article-title":"Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis","volume":"17","author":"Thompson","year":"2016","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1756286418775375","article-title":"MRI features as a helpful tool to predict the molecular subgroups of medulloblastoma: state of the art","volume":"11","author":"Colafati","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3171\/2019.5.peds18381","article-title":"Medulloblastoma in the age of molecular subgroups: a review: JNSPG 75th Anniversary Invited Review Article","volume":"24","author":"Juraschka","year":"2019","journal-title":"J Neurosurgery: Pediatr PED"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1569-6","article-title":"Risk stratification of childhood medulloblastoma in the molecular era: the current consensus","volume":"131","author":"Ramaswamy","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","article-title":"Intertumoral heterogeneity within medulloblastoma subgroups","volume":"31","author":"Cavalli","year":"2017","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.cell.2018.05.033","article-title":"A hematogenous route for medulloblastoma leptomeningeal metastases","volume":"172","author":"Garzia","year":"2018","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.67.2428","article-title":"Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters","volume":"34","author":"von Bueren","year":"2016","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.01.015","article-title":"Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT\u201991","volume":"45","author":"Hoff","year":"2009","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.12.017","article-title":"Outcome for patients with metastatic (M2\u20133) medulloblastoma treated with SIOP\/UKCCSG PNET-3 chemotherapy","volume":"41","author":"Taylor","year":"2005","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(06)70867-1","article-title":"Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial","volume":"7","author":"Gajjar","year":"2006","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 world health organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12837","article-title":"Pathology, diagnostics, and classification of medulloblastoma","volume":"30","author":"Orr","year":"2020","journal-title":"Brain Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0800-8","article-title":"Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH\/WNT molecular subgroups","volume":"121","author":"Ellison","year":"2011","journal-title":"Acta Neuropathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0922-z","article-title":"Molecular subgroups of medulloblastoma: the current consensus","volume":"123","author":"Taylor","year":"2012","journal-title":"Acta Neuropathol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.78","article-title":"The clinical implications of medulloblastoma subgroups","volume":"8","author":"Northcott","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.04.4974","article-title":"Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations","volume":"24","author":"Thompson","year":"2006","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/biology12020267","article-title":"Medulloblastoma: From TP53 mutations to molecular classification and liquid biopsy","volume":"12","author":"Eibl","year":"2023","journal-title":"Biology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.48.5052","article-title":"Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma","volume":"31","author":"Zhukova","year":"2013","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae178","article-title":"Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: a multicenter cohort study","volume":"27","author":"Schwalbe","year":"2025","journal-title":"Neuro Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-019-02020-0","article-title":"Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes","volume":"138","author":"Sharma","year":"2019","journal-title":"Acta Neuropathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ccell.2014.11.002","article-title":"Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease","volume":"27","author":"Hill","year":"2015","journal-title":"Cancer Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.05.013","article-title":"Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma","volume":"12","author":"Hanaford","year":"2019","journal-title":"Transl Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s12885-020-07008-8","article-title":"INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I\/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk Malignancies","volume":"20","author":"van Tilburg","year":"2020","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2023.101189","article-title":"Proton radiotherapy for management of medulloblastoma: a systematic review of clinical outcomes","volume":"8","author":"Young","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/neuonc\/nos267","article-title":"Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children\u2019s Oncology Group trial A9961","volume":"15","author":"Packer","year":"2013","journal-title":"Neuro Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02730","article-title":"Children\u2019s oncology group phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma","volume":"39","author":"Michalski","year":"2021","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/nop\/npw013","article-title":"Core deficits and quality of survival after childhood medulloblastoma: a review","volume":"4","author":"Chevignard","year":"2017","journal-title":"Neuro-Oncol Pract"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/0284186x.2017.1324207","article-title":"A review of dosimetric and toxicity modeling of proton versus photon craniospinal irradiation for pediatrics medulloblastoma","volume":"56","author":"Ho","year":"2017","journal-title":"Acta Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01706","article-title":"Superior intellectual outcomes after proton radiotherapy compared with photon radiotherapy for pediatric medulloblastoma","volume":"38","author":"Kahalley","year":"2020","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00261","article-title":"Secondary Malignancy risk following proton radiation therapy","volume":"5","author":"Eaton","year":"2015","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1101\/gad.349538.122","article-title":"Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma","volume":"36","author":"Eisemann","year":"2022","journal-title":"Genes Dev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02746","article-title":"Allies or enemies-the multifaceted role of myeloid cells in the tumor microenvironment","volume":"10","author":"Haas","year":"2019","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11864-021-00874-9","article-title":"Immunosuppression in medulloblastoma: insights into cancer immunity and immunotherapy","volume":"22","author":"Audi","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.23233","article-title":"Roles and interactions of tumor microenvironment components in medulloblastoma with implications for novel therapeutics","volume":"63","author":"Yang","year":"2024","journal-title":"Genes Chromosomes Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152629","article-title":"VISTA emerges as a promising target against immune evasion mechanisms in medulloblastoma","volume":"16","author":"Mu\u00f1oz Perez","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/s41467-019-10458-9","article-title":"Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma","volume":"10","author":"Maximov","year":"2019","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2005828","article-title":"Brain cancer uses TGF-\u03b2 to battle immune cells","volume":"7","author":"Berndt","year":"2014","journal-title":"Sci Signaling"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1462430","article-title":"Subgroup-specific immune and stromal microenvironment in medulloblastoma","volume":"7","author":"Bockmayr","year":"2018","journal-title":"Oncoimmunology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3125.dnarepair16-ia11","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41467-025-56268-0","article-title":"Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics","volume":"16","author":"Velz","year":"2025","journal-title":"Nat Commun"},{"key":"B47","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11060-010-0378-3","article-title":"Characterization of signaling function and expression of HLA class I molecules in medulloblastoma","volume":"103","author":"Smith","year":"2011","journal-title":"J Neuro-Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-18-0940","article-title":"Systemic interferon-\u03b3 increases MHC class I expression and T-cell infiltration in cold tumors: results of a phase 0 clinical trial","volume":"7","author":"Zhang","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.05.002","article-title":"Coinhibitory pathways in the B7-CD28 ligand-receptor family","volume":"44","author":"Schildberg","year":"2016","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2002796","article-title":"Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation","volume":"5","author":"Patsoukis","year":"2012","journal-title":"Sci Signaling"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.6.2533","article-title":"CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells","volume":"183","author":"Krummel","year":"1996","journal-title":"J Exp Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1172\/jci80011","article-title":"Anti\u2013PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-021-00683-y","article-title":"Emerging role of PD-1 in the central nervous system and brain diseases","volume":"37","author":"Zhao","year":"2021","journal-title":"Neurosci Bull"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/s0378-1119(97)00260-6","article-title":"The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors","volume":"197","author":"Finger","year":"1997","journal-title":"Gene"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/8.5.765","article-title":"Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes","volume":"8","author":"Agata","year":"1996","journal-title":"Int Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1398877","article-title":"Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma","volume":"7","author":"Vermeulen","year":"2018","journal-title":"OncoImmunology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24951","article-title":"PD-L1 expression in medulloblastoma: an evaluation by subgroup","volume":"9","author":"Martin","year":"2018","journal-title":"Oncotarget"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2886-5","article-title":"PD-1\/PD-L1 and immune-related gene expression pattern in pediatric Malignant brain tumors: clinical correlation with survival data in Korean population","volume":"139","author":"Hwang","year":"2018","journal-title":"J Neuro-Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2226-9","article-title":"Regulatory mechanisms of PD-L1 expression in cancer cells","volume":"67","author":"Shi","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/po.20.00412","article-title":"Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review","volume":"5","author":"Prince","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194789","article-title":"PD-L1 expression by RNA-sequencing in non-small cell lung cancer: concordance with immunohistochemistry and associations with pembrolizumab treatment outcomes","volume":"15","author":"Nesline","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.17305\/bjbms.2022.7953","article-title":"PD-L1 testing by immunohistochemistry in immuno-oncology","volume":"23","author":"Vranic","year":"2023","journal-title":"Biomol BioMed"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1581275","article-title":"Unraveling the complexity of PD-L1 assays: a descriptive review of the methodology, scoring, and practical implications","volume":"15","author":"Vainer","year":"2025","journal-title":"Front Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.12.026","article-title":"The International Association for the Study of Lung Cancer global survey on programmed death-ligand 1 testing for NSCLC","volume":"16","author":"Mino-Kenudson","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-21-505","article-title":"PD-L1 immunohistochemistry comparison of 22C3 and 28\u20138 assays for gastric cancer","volume":"12","author":"Narita","year":"2021","journal-title":"J Gastrointestinal Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae165.0963","article-title":"Dual targeting of CD155\/TIGIT and PD-L1\/PD-1 immune checkpoints potentiates NK cell-mediated cytotoxicity in medulloblastoma","volume":"7","author":"Monnikhof","year":"2025","journal-title":"Neuro-Oncology Adv"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-0713","article-title":"Differential immune microenvironments and response to immune checkpoint blockade among molecular subtypes of murine medulloblastoma","volume":"22","author":"Pham","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semcancer.2020.06.016","article-title":"Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer","volume":"79","author":"Gaynor","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1600-065x.2009.00770.x","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol Rev"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.106043","article-title":"Profiling tumour-infiltrating immune cells in a large paediatric medulloblastoma cohort: a retrospective analysis","volume":"122","author":"Chen","year":"2025","journal-title":"EBioMedicine"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2013.03.003","article-title":"Structure and T cell inhibition properties of B7 family member, B7-H3","volume":"21","author":"Vigdorovich","year":"2013","journal-title":"Structure"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.62347\/iltr3848","article-title":"The relevance of B7-H3 and tumor-associated macrophages in the tumor immune microenvironment of solid tumors: recent advances","volume":"17","author":"Luan","year":"2025","journal-title":"Am J Transl Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s40425-019-0816-5","article-title":"High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation","volume":"7","author":"MacGregor","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/85339","article-title":"B7-H3: A costimulatory molecule for T cell activation and IFN-\u03b3 production","volume":"2","author":"Chapoval","year":"2001","journal-title":"Nat Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.4.2352","article-title":"Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains","volume":"172","author":"Steinberger","year":"2004","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13000-025-01645-y","article-title":"High B7-H3 protein expression in medulloblastoma is associated with metastasis and unfavorable patient outcomes","volume":"20","author":"Font\u00e3o","year":"2025","journal-title":"Diagn Pathol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3892\/or.2023.8556","article-title":"Targeting B7-H3 through EZH2 inhibition in MYC-positive Group 3 medulloblastoma","volume":"49","author":"Shishido","year":"2023","journal-title":"Oncol Rep"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8081158","article-title":"Role of MYC-miR-29-B7-H3 in medulloblastoma growth and angiogenesis","volume":"8","author":"Purvis","year":"2019","journal-title":"J Clin Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.11.006","article-title":"B7\u2013H3 as a prognostic biomarker and therapeutic target in pediatric central nervous system tumors","volume":"13","author":"Maachani","year":"2020","journal-title":"Transl Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02762-y","article-title":"Pediatric medulloblastoma express immune checkpoint B7-H3","volume":"24","author":"Li","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12829","article-title":"MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7-H3)","volume":"30","author":"Kanchan","year":"2020","journal-title":"Brain Pathol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-12-0715","article-title":"Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity","volume":"18","author":"Loo","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-0432","article-title":"CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c02850","article-title":"Multivalent, bispecific \u03b1B7-H3-\u03b1CD3 chemically self-assembled nanorings direct potent T cell responses against medulloblastoma","volume":"16","author":"Mews","year":"2022","journal-title":"ACS Nano"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody\u2013drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.044","article-title":"380TiP A phase I\/II dose-escalation and expansion cohort study of intracerebroventricular radioimmunotherapy using 177-Lu-DTPA-omburtamab in pediatric and adolescent patients with recurrent or refractory medulloblastoma","volume":"32","author":"Khatua","year":"2021","journal-title":"Ann Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11060-022-04235-w","article-title":"Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymoma","volume":"162","author":"Tringale","year":"2023","journal-title":"J Neuro-Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.85813","article-title":"B7-H3 in brain Malignancies: immunology and immunotherapy","volume":"19","author":"Guo","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.11.1807","article-title":"Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8","volume":"25","author":"Kramer","year":"2007","journal-title":"J Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/77.3.739","article-title":"Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice","volume":"77","author":"Cheung","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"B97","first-page":"252124","article-title":"Biodistribution and radiation dosimetry of first-in human intrathecal Lu-177 omburtamab in a trial to treat pediatric patients with relapsed medulloblastoma","volume":"66","author":"Wong","year":"2025","journal-title":"J Nucl Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad031","article-title":"Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS Malignancies: Safety, efficacy, biomarker, and pharmacokinetics\u2014CheckMate 908","volume":"25","author":"Dunkel","year":"2023","journal-title":"Neuro-Oncology"},{"key":"B99","doi-asserted-by":"publisher","first-page":"iv111","DOI":"10.1093\/neuonc\/noae064.379","article-title":"IMMU-08. Outcome of patients with recurrent medulloblastoma and ependymoma treated with pembrolizumab, an immune checkpoint inhibitor: A pediatric brain tumor consortium study (PBTC045)","volume":"26","author":"Hwang","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.117","article-title":"Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer","volume":"108","author":"Quezada","year":"2013","journal-title":"Br J Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox109","article-title":"Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma","volume":"19","author":"Kieran","year":"2017","journal-title":"Neuro Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-1425","article-title":"Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study","volume":"19","author":"Gajjar","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1200\/po.19.00264","article-title":"Vismodegib as first-line treatment of mutated sonic hedgehog pathway in adult medulloblastoma","volume":"4","author":"Kian","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.60.1591","article-title":"Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: Results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032","volume":"33","author":"Robinson","year":"2015","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26754","article-title":"A phase II study of radioimmunotherapy with intraventricular (131) I-3F8 for medulloblastoma","volume":"65","author":"Kramer","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.2522","article-title":"Eradication of medulloblastoma by NKG2D-specific CAR T-cells","volume":"38","author":"Dai","year":"2020","journal-title":"J Clin Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-1880","article-title":"GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma","volume":"30","author":"Ciccone","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27389","article-title":"EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma","volume":"10","author":"Ravanpay","year":"2019","journal-title":"Oncotarget"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-06-4309","article-title":"Regression of experimental medulloblastoma following transfer of HER2-specific T cells","volume":"67","author":"Ahmed","year":"2007","journal-title":"Cancer Res"},{"key":"B111","unstructured":"FDA approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection\n          \n          \n          \n          2025"},{"key":"B112","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1097\/mph.0000000000001339","article-title":"Nivolumab in the treatment of recurrent or refractory pediatric brain tumors: A single institutional experience","volume":"41","author":"Gorsi","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab196.224","article-title":"CTIM-32. Immune checkpoint inhibitor nivolumab in people with recurrent select rare CNS cancers: Results of interim analysis in a heavily pretreated cohort","volume":"23","author":"Penas-Prado","year":"2021","journal-title":"Neuro-Oncology"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B116","unstructured":"FDA approves nivolumab with ipilimumab for unresectable or metastatic hepatocellular carcinoma\n          \n          \n          \n          2025"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29031","article-title":"Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial","volume":"68","author":"Levy","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npae114","article-title":"Children with medulloblastoma treated with modified ACNS0821 temozolomide, irinotecan, and bevacizumab: The Seattle Children\u2019s Hospital experience","volume":"12","author":"Ronsley","year":"2024","journal-title":"Neuro-Oncology Pract"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B120","doi-asserted-by":"publisher","first-page":"911260","DOI":"10.21203\/rs.3.rs-816357\/v1","article-title":"Molecular profile reveals immune-associated markers of medulloblastoma for different subtypes","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1062856","article-title":"Digital expression profile of immune checkpoint genes in medulloblastomas identifies CD24 and CD276 as putative immunotherapy targets","volume":"14","author":"Marques","year":"2023","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1084\/jem.201006432011512c","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000497","article-title":"New emerging targets in cancer immunotherapy: the role of TIM3","volume":"4","author":"Friedlaender","year":"2019","journal-title":"ESMO Open"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-14-0039","article-title":"Tim-3: An emerging target in the cancer immunotherapy landscape","volume":"2","author":"Anderson","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215387","article-title":"Immunotherapy in medulloblastoma: Current state of research, challenges, and future perspectives","volume":"13","author":"Voskamp","year":"2021","journal-title":"Cancers"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/ni988","article-title":"Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance","volume":"4","author":"Sabatos","year":"2003","journal-title":"Nat Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.12659\/msm.903098","article-title":"Combined blockade of T cell immunoglobulin and mucin domain 3 and carcinoembryonic antigen-related cell adhesion molecule 1 results in durable therapeutic efficacy in mice with intracranial gliomas","volume":"23","author":"Li","year":"2017","journal-title":"Med Sci Monit"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.02.002","article-title":"PSGL-1: A new player in the immune checkpoint landscape","volume":"38","author":"Tinoco","year":"2017","journal-title":"Trends Immunol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(01)00399-3","article-title":"Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLeX and PSGL-1","volume":"103","author":"Somers","year":"2000","journal-title":"Cell"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"key":"B131","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s40364-024-00693-8","article-title":"A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy","volume":"12","author":"Peng","year":"2024","journal-title":"biomark Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1002\/glia.23517","article-title":"VISTA expression by microglia decreases during inflammation and is differentially regulated in CNS diseases","volume":"66","author":"Borggrewe","year":"2018","journal-title":"Glia"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J Exp Med"},{"key":"B134","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-443-14064-8.90009-2","article-title":"Next generation immune checkpoints","volume-title":"Reference Module in Biomedical Sciences","author":"Mu\u00f1oz Perez","year":"2024"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0313-5","article-title":"VISTA expressed in tumour cells regulates T cell function","volume":"120","author":"Mulati","year":"2019","journal-title":"Br J Cancer"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2023-972","article-title":"Abstract 972: VISTA expression in patients with advanced solid tumors: A potential biomarker in VISTA-101 clinical trial","volume":"83","author":"Kabi","year":"2023","journal-title":"Cancer Res"},{"key":"B137","doi-asserted-by":"publisher","first-page":"TPS2664","DOI":"10.1200\/jco.2023.41.16_suppl.tps2664","article-title":"A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors","volume":"41","author":"Ahnert","year":"2023","journal-title":"J Clin Oncol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s12094-022-02975-9","article-title":"CD155 is a putative therapeutic target in medulloblastoma","volume":"25","author":"Li","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1456-0","article-title":"CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy","volume":"572","author":"Barkal","year":"2019","journal-title":"Nature"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae178","article-title":"Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: A multicenter cohort study","volume":"27","author":"Schwalbe","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030586","article-title":"The current status of immune checkpoint inhibitors in neuro-oncology: A systematic review","volume":"12","author":"Brahm","year":"2020","journal-title":"Cancers"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04803-1","article-title":"Off-label use of immune checkpoint inhibitors for the treatment of solid tumors: analysis of a nationwide patient sample","volume":"149","author":"Kandemir","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad184","article-title":"The role of radiotherapy in immunotherapy strategies in the central nervous system","volume":"26","author":"Gallitto","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1725230\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T10:27:09Z","timestamp":1778236029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1725230\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":144,"alternative-id":["10.3389\/fonc.2026.1725230"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1725230","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1725230"}}